DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call Transcript

Scott Kellen: Yes. Again, we haven’t disclosed those numbers specifically other than noted that it’s obviously a significant driver of the increase, Alex. And principally, what we got to get our arms around relative to the appeal is, can we put any kind of bands or caps on this fees. So that we don’t put our current cash runway at risk. Okay, so in other words, if it costs too much, that could be a determining factor in moving forward.

Alex Nowak: So if you decide not to move forward with an appeal, I’m sure you must have some sort of — you must know what the damage amount is generally. So I assume it’s not material enough to disclose. Is that right?

Scott Kellen: I’m not sure I understand. The court found no sufficient causal link. So at this point, if we don’t appeal, I don’t think they’ll change that conclusion.

Alex Nowak: Okay. Well, I guess the — reading the court document, it looked like the court wanted you to pay PRA’s legal fees. I’m just trying to understand what their legal fees ultimately is.

Scott Kellen: No. No, we don’t have exposure for that. The Dutch Courts operate a little differently. They have an assigned amount that they charged us, and we had to pay that. But it wasn’t determined based upon their costs. It was around USD 40,000.

Operator: And seeing no further questions, I’ll turn the call back over to our host.

Dietrich Pauls: Great. We would like to thank everyone for joining us this morning and for your continued support. We’re building momentum in our ReMEDy2 trial and look forward to the next update. This concludes our call today. Thank you.

Operator: The meeting has now concluded. Thank you for joining, and have a pleasant day.